AU3745395A - Microorganisms as therapeutic delivery systems - Google Patents
Microorganisms as therapeutic delivery systemsInfo
- Publication number
- AU3745395A AU3745395A AU37453/95A AU3745395A AU3745395A AU 3745395 A AU3745395 A AU 3745395A AU 37453/95 A AU37453/95 A AU 37453/95A AU 3745395 A AU3745395 A AU 3745395A AU 3745395 A AU3745395 A AU 3745395A
- Authority
- AU
- Australia
- Prior art keywords
- microorganisms
- delivery systems
- therapeutic delivery
- therapeutic
- systems
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 244000005700 microbiome Species 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI94A2025 | 1994-10-05 | ||
ITMI942025A IT1270123B (en) | 1994-10-05 | 1994-10-05 | PHARMACEUTICAL COMPOSITIONS CONTAINING ENGINEERED MICROORGANISMS AND THEIR USE FOR THERAPY |
PCT/EP1995/003921 WO1996011277A1 (en) | 1994-10-05 | 1995-10-04 | Microorganisms as therapeutic delivery systems |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3745395A true AU3745395A (en) | 1996-05-02 |
Family
ID=11369649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU37453/95A Abandoned AU3745395A (en) | 1994-10-05 | 1995-10-04 | Microorganisms as therapeutic delivery systems |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0784689A1 (en) |
JP (1) | JPH10506791A (en) |
AU (1) | AU3745395A (en) |
CA (1) | CA2201721A1 (en) |
IT (1) | IT1270123B (en) |
WO (1) | WO1996011277A1 (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190657B1 (en) | 1995-06-07 | 2001-02-20 | Yale University | Vectors for the diagnosis and treatment of solid tumors including melanoma |
GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
EP1012232B1 (en) | 1997-09-10 | 2009-10-28 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
DE69914932T2 (en) * | 1998-10-20 | 2004-12-09 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | USE OF A CYTOKINE-PRODUCING LACTOCOCCUS TRIBE FOR TREATING COLUMN |
FR2791998B1 (en) * | 1999-04-07 | 2001-06-08 | Agronomique Inst Nat Rech | MODIFIED LACTOCOCCUS EXPRESSING CATALASE AND USES THEREOF |
US7220418B1 (en) * | 1999-07-05 | 2007-05-22 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Delivery of trefoil peptides |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
AU8467201A (en) * | 2000-07-27 | 2002-02-13 | Univ Pennsylvania | Compositions for and methods of using herpes simplex virus glycoprotein d to suppress immune responses |
CA2342040C (en) | 2000-09-21 | 2012-07-10 | Kyowa Hakko Kogyo Co., Ltd. | Anaerobic bacterium as a drug for cancer gene therapy |
US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
AU2003210688A1 (en) * | 2002-01-31 | 2003-09-02 | Symbigene, Inc. | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US7179458B2 (en) | 2002-03-08 | 2007-02-20 | Osel, Inc. | Lactobacilli expressing biologically active polypeptides and uses thereof |
JP2005529622A (en) * | 2002-06-19 | 2005-10-06 | ヴェーイーベー・ヴェーゼットウェー | Methods and means for promoting intestinal absorption |
JP2007503845A (en) * | 2003-01-29 | 2007-03-01 | オセル, インコーポレイテッド | Surface expression of biologically active proteins in bacteria |
ATE511848T1 (en) | 2004-08-25 | 2011-06-15 | Us Gov Health & Human Serv | LIVE MICROBIAL MICROBICIDES |
KR101187625B1 (en) | 2004-09-10 | 2012-10-05 | 도쿠리츠다이가쿠호징 가나자와다이가쿠 | Vaccine for oral administration |
US7456011B2 (en) | 2005-01-12 | 2008-11-25 | Osel, Inc. | Modified cyanovirin-n polypeptide |
DK2119450T3 (en) | 2005-11-29 | 2013-05-06 | Actogenix Nv | Induction of mucosal tolerance to pancreatic islet beta cell autoantigens |
US20090074734A1 (en) * | 2006-05-02 | 2009-03-19 | Actogenix N.V. | Microbial intestinal delivery of obesity related peptides |
ES2595729T3 (en) | 2007-01-12 | 2017-01-03 | Intrexon Actobiotics Nv | Lactococcus promoters and their uses |
ES2492468T3 (en) | 2007-01-25 | 2014-09-09 | Actogenix N.V. | Treatment of immune disease by administration through the antigen mucosa using genetically modified Lactobacillus |
EP3181682B1 (en) | 2008-09-29 | 2021-04-21 | Intrexon Actobiotics NV | Reduced colonization of microbes at the mucosa |
DK2424972T3 (en) | 2009-04-30 | 2013-10-14 | Actogenix Nv | Cryoprotectants for freeze-drying of lactic acid bacteria |
WO2011039137A1 (en) | 2009-09-29 | 2011-04-07 | Actogenix N.V. | Lactobacillus and streptococcus promoters and uses thereof |
AU2011206532B8 (en) | 2010-01-14 | 2015-08-06 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Recombinant probiotic bacteria for the prevention and treatment of inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
FR2960001A1 (en) * | 2010-05-12 | 2011-11-18 | Univ Rennes | RECOMBINANT VECTOR FOR THE PRODUCTION AND SECRETION OF AMINO ACID SEQUENCES OF INTEREST BY PROPIONIC BACTERIA AND ITS APPLICATIONS |
US9476056B2 (en) | 2010-05-12 | 2016-10-25 | Universite De Rennes 1 | Recombinant vector for producing and secreting peptide or protein of interest by propionibacteria and applications thereof |
US20130164380A1 (en) | 2010-06-17 | 2013-06-27 | Actogenix Nv | Compositions and methods for treating inflammatory conditions |
CN101921725B (en) * | 2010-07-27 | 2013-06-05 | 浙江大学 | Converter for inhibiting hen somatostatin action through oral immunization and application thereof |
CN103917639B (en) | 2011-09-23 | 2017-09-26 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | Gram-positive bacterium through modification and application thereof |
EP2758512B1 (en) | 2011-09-23 | 2018-05-09 | Intrexon Actobiotics NV | Modified gram positive bacteria and uses thereof |
WO2014025938A1 (en) | 2012-08-07 | 2014-02-13 | TopGeniX, Inc. | Topical composition comprising transformed bacteria expressing a compound of interest |
US10064797B2 (en) | 2014-06-17 | 2018-09-04 | TopGeniX, Inc. | Topical formulations for UV protection |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
KR102602358B1 (en) | 2019-03-04 | 2023-11-17 | 아우리얼리스 테라퓨틱스 아게 | Chloride-inducible prokaryotic expression system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1321962C (en) * | 1985-03-20 | 1993-09-07 | Aizo Matsushiro | Dental caries preventive preparations and method for preparing said preparations |
-
1994
- 1994-10-05 IT ITMI942025A patent/IT1270123B/en active IP Right Grant
-
1995
- 1995-10-04 JP JP8512318A patent/JPH10506791A/en active Pending
- 1995-10-04 CA CA002201721A patent/CA2201721A1/en not_active Abandoned
- 1995-10-04 WO PCT/EP1995/003921 patent/WO1996011277A1/en not_active Application Discontinuation
- 1995-10-04 AU AU37453/95A patent/AU3745395A/en not_active Abandoned
- 1995-10-04 EP EP95935431A patent/EP0784689A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO1996011277A1 (en) | 1996-04-18 |
EP0784689A1 (en) | 1997-07-23 |
IT1270123B (en) | 1997-04-28 |
ITMI942025A0 (en) | 1994-10-05 |
JPH10506791A (en) | 1998-07-07 |
ITMI942025A1 (en) | 1996-04-05 |
CA2201721A1 (en) | 1996-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3745395A (en) | Microorganisms as therapeutic delivery systems | |
AU4129396A (en) | Diketopiperazine-based delivery systems | |
AU2946295A (en) | Targeted gene delivery system | |
AU664807B2 (en) | Drug delivery system | |
AU5441496A (en) | Fluid Delivery System | |
AU3050892A (en) | Delivery system | |
AU3204995A (en) | Closed drug delivery system | |
AU3532195A (en) | Medicaments | |
AU1928495A (en) | Apheresis system | |
AU2841995A (en) | Patient support systems | |
AU2816297A (en) | Recipient-dosage delivery system | |
AU2999995A (en) | Self-emulsifying drug delivery system | |
AU3257495A (en) | Molecular presenting system | |
AU4267396A (en) | Modified cannula | |
AU7105996A (en) | Bacterial delivery system | |
AU2725795A (en) | Tournament system | |
AU5092099A (en) | Vibroacoustic delivery system | |
AU4344996A (en) | Vessel-puncturing cannula | |
AU5105398A (en) | Hydrocolloid delivery system | |
AU3991695A (en) | Ranging system | |
AU2547895A (en) | Therapeutic phenoxyalkylheterocycles | |
AU1671997A (en) | Drug delivery system using galactoxyloglucan | |
AU7164996A (en) | Constituent delivery system | |
AU7636296A (en) | Ampoule system | |
AU6510094A (en) | Drug delivery system |